Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice

Neuroscience

Volumn 85, Issue 3, 1998, Pages 907-917

  Asanuma, M ^a   Hirata, H ^a   Cadet, J L ^a  

^a Intramural Research Program   (United States)

Author keywords

6 hydroxydopamine; Dopamine transporter; Parkinson's disease; Superoxide anion; Superoxide dismutase; Transgenic mice

Indexed keywords

OXIDOPAMINE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ARTICLE; DOPAMINE BRAIN LEVEL; DOPAMINE UPTAKE; ENZYME ACTIVITY; MALE; MOUSE; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; CARRIER PROTEINS; CORPUS STRIATUM; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FUNCTIONAL LATERALITY; IODINE RADIOISOTOPES; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, TRANSGENIC; MUTATION; NERVE TISSUE PROTEINS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; SUBSTANTIA NIGRA; SUPEROXIDE DISMUTASE; SYMPATHOLYTICS; TYROSINE 3-MONOOXYGENASE;

EID: 0031946038     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-4522(97)00665-9     Document Type: Article

References (46)

1. Adams J. D. J., Odunze I. N. Oxygen free radicals and Parkinson's disease. Free Radical Biol. Med. 10:1991;161-169.
2. Ambani L. M., Van Woert M. H., Murphy S. Brain peroxidase and catalase in Parkinson's disease. Archs Neurol. 32:1975;114-118.
3. Asanuma M., Ogawa N., Nishibayashi S., Kawai M., Kondo Y., Iwata E. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain. Archs int. Pharmacodyn. Ther. 329:1995;221-230.
4. Ben-Shachar D., Eshel G., Finberg J. P. M., Youdim M. B. H. The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J. Neurochem. 56:1991;1441-1444.
5. Berger K., Przedborski S., Cadet J. L. Retrograde degeneration of nigrostriatal neurons induced by intrastriatal 6-hydroxydopamine injection in rats. Brain Res. Bull. 26:1991;301-307.
6. Bindoff L. A., Birch-Machin M., Cartlidge N. E. F., Parker J. R., Turnbull D. M. Mitochondrial function in Parkinson's disease. Lancet. ii:1989;49.
7. 125I]iodophenyl)tropan-2-carboxylic acid isopropyl ester. Molec. Pharmac. 47:1995;779-786.
8. Breese G. R., Traylor T. D. Effects of 6-hydroxydopamine on brain norepinephrine and dopamine: evidence for selective degeneration of catecholamine neurons. J. Pharmac. exp. Ther. 174:1970;413-420.
9. Cadet J. L. A unifying hypothesis of movement and madness: involvement of free radicals in disorders of the isodendritic core. Med. Hypotheses. 27:1988;87-94.
10. Cadet J. L. and Brannock C. (1998) Free radicals and the pathobiology of brain dopamine systems. Neurochem. Int. (in press).
11. Cadet J. L., Ladenheim B., Baum I., Carlson E., Epstein C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA). Brain Res. 655:1994;259-262.
12. Cadet J. L., Ladenheim B., Hirata H., Rothman R. B., Ali S., Carlson E., Epstein C., Moran T. H. Superoxide radicals mediate the biochemical effects of methlenedioxymethamphetamine (MDMA): evidence from using CuZn-superoxide dismutase transgenic mice. Synapse. 21:1995;169-176.
13. Cadet J. L., Last R., Kostic V., Przedborski S., Jackson-Lewis V. Long-term behavioral and biochemical effects of intrastriatal injections of 6-hydroxydopamine. Brain Res. Bull. 26:1991;707-713.
14. Cadet J. L., Sheng P., Ali S., Rothman R., Carlson E., Epstein C. J. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice. J. Neurochem. 62:1994;380-383.
15. Cadet J. L., Zhu S. M. The intrastriatal 6-hydroxydopamine model of hemiparkinsonism: quantitative receptor autoradiographic evidence of correlation between circling behavior and presynaptic as well as postsynaptic nigrostriatal markers in the rat. Brain Res. 595:1992;316-326.
16. Chacon J. N., Chedekel M. R., Land E. J., Truscott T. G. Chemically induced Parkinson's disease: intermediates in the oxidation of 1-methyl-4-phenylpyridinium ion. Biochem. biophys. Res. Commun. 144:1987;957-964.
17. Clow A., Hussain T., Glover V., Sandler M., Walker M., Dexter D. Pergolide can induce soluble superoxide dismutase in rat striata. J. neural Transm. 90:1992;27-31.
18. Cohen G. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv. Neurol. 45:1986;119-125.
19. Cohen G., Heikkila R. E. The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. biol. Chem. 249:1974;2447-2452.
20. Cubells J. F., Rayport S., Rajndron G., Sulzer D. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress. J. Neurosci. 14:1994;2260-2271.
21. De Vito M. J., Wagner G. C. Methamphetamine-induced neuronal damage: a possible role for free radicals. Neuropharmacology. 28:1989;1145-1150.
22. Dexter D. T., Wells F. R., Lees A. J., Agid Y., Jenner P., Marsden C. D. Increase nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1989;1830-1836.
23. Epstein C. J., Avraham K. B., Lovett M., Smith S., Elroy-Stein O., Rotman G., Bry C., Groner Y. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. Proc. natn. Acad. Sci. U.S.A. 84:1987;8044-8048.
24. Giovanni A., Liang L. P., Hastings T. G., Zigmond M. J. Estimating hydroxyl radical content in rat brain using systemic and intraventricular salicylate: impact of methamphetamine. J. Neurochem. 64:1995;1819-1825.
25. Halliwell B. Reactive oxygen species and the central nervous system. J. Neurochem. 59:1992;1609-1623.
26. Halliwell B., Gutteridge J. M. C. Oxygen radicals and nervous system. Trends Neurosci. 8:1985;22-26.
27. Heikkila R. E., Cohen G. 6-Hydroxydopamine: evidence for superoxide radical as an oxidative intermediate. Science. 181:1973;456-457.
28. Hirata H., Ladenheim B., Carlson E., Epstein C., Cadet J. L. Autoradiographic evidence for methamphetamine induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res. 714:1996;95-103.
29. Kish S. J., Morito C., Hornykiewicz O. Glutathione peroxidase activity in Parkinson's disease. Neurosci. Lett. 58:1985;343-346.
30. Kostrzewa R., Jacobowitz D. Pharmacological actions of 6-hydroxydopamine. Pharmac. Rev. 26:1974;199-288.
31. Michel P. P., Hefti F. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 26:1990;428-435.
32. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. biophys. Res. Commun. 163:1989;1450-1455.
33. +) in ventral mesencephalic-striatal co-culture in rat. Neurosci. Lett. 170:1994;191-194.
34. Ogawa N., Asanuma M., Kondo Y., Hirata H., Nishibayashi S., Mori A. Changes in lipid peroxidation, Cu/Zn-superoxide dismutase and its mRNA following an intracerebroventricular injection of 6-hydroxydopamine in mice. Brain Res. 646:1994;337-340.
35. Ogawa N., Asanuma M., Kondo Y., Kawada Y., Yamamoto M., Mori A. Differential effects of chronic L-DOPA treatment on lipid peroxydation in the mouse brain with or without pretreatment with 6-hydroxydopamine. Neurosci. Lett. 171:1994;55-58.
36. Ogawa N., Tanaka K., Asanuma M., Kawai M., Masumizu T., Kohno M., Mori A. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res. 657:1994;207-213.
37. Olanow C. W. and Cohen G. (1992) The pathogenesis of Parkinson's disease. In The Scientific Basis for the Treatment of Parkinson's Disease (eds Olanow C. W. and Lieberman A. N.), pp. 59-76. The Parthenon Publishing Group, Lancashire, U.K.
38. Przedborski S., Levivier M., Jiang H., Ferreira M., Jackson-Lewis V., Donaldson D., Togasaki D. M. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience. 67:1995;631-647.
39. Riederer P., Sofic E., Rausch W. D., Schmidt B., Reynolds G. P., Kellinger K., Youdim M. B. H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J. Neurochem. 52:1989;515-520.
40. Seiden L. S., Vosmer G. Formation of 6-hydroxydopamine in caudate nucleus of the rat brain after a single large dose of methylamphetamine. Pharmac. Biochem. Behav. 21:1984;29-31.
41. +): reductive activation by NADPH cytochrome P450 reductase. Biochem. biophys. Res. Commun. 135:1986;583-588.
42. Slotnick B. M. and Leonard C. M. (1975) A Stereotaxic Atlas of the Albino Mouse Forebrain. DHEW Publications, Rockville, MD.
43. Tiffani-Castiglioni E., Saneto R. P., Proctor P. H., Perez-Polo J. R. Participation of active oxygen species in 6-hydroxydopamine toxicity to a human neuroblastoma cell line. Biochem. Pharmac. 31:1982;181-188.
44. Ungerstedt U. 6-Hydroxydopamine induced degeneration of central monoamine neurons. Eur. J. Pharmac. 5:1968;107-110.
45. Wagner G. C., Carelli R. M., Jarvis M. F. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats. Res. Commun. chem. Pathol. Pharmac. 47:1985;221-228.
46. Ziv I., Melamed E., Nardi N., Luria D., Achiron A., Offen D., Barzilai A. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci. Lett. 170:1994;136-140.